Kolexia
Soussain Carole Oncologie médicale
Soussain Carole
Oncologie médicale
Institut Curie
Saint-Cloud, France
183 Activités
48 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Tumeurs du système nerveux central Récidive tumorale locale Lymphome B diffus à grandes cellules Lymphome malin non hodgkinien Lymphome intraoculaire Tumeurs de la rétine Maladie de Hodgkin COVID-19

Collaborateurs

Voir plus
Houillier Caroline
Houillier Caroline
Hôpital Pitie Salpetriere, Paris, France
Hoang-Xuan Khe
Hoang-Xuan Khe
Hôpital Pitie Salpetriere, Paris, France
Choquet Sylvain
Choquet Sylvain
Hôpital Pitie Salpetriere, Paris, France
Touitou Valerie
Touitou Valerie
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
Janssen
20 collaboration(s)
Dernière en 2023
Gilead
2 collaboration(s)
Dernière en 2022
Sanofi
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Analysis of cerebrospinal fluid for the diagnosis of CNS lymphoma: Comparison of the ESCCA/ISCCA protocol and real-world data of the CytHem/LOC French network.
Cytometry. Part B, Clinical cytometry   07 mars 2024
Étude prospective multicentrique du réseau LOC : TEP intérim dans le lymphome primitif du système nerveux central
10e Journées Francophones de Médecine nucléaire - Biarritz   01 mars 2024
Interim FDG-PET improves treatment failure prediction in primary central nervous system Lymphoma: a LOC network prospective multicentric study.
Neuro-oncology   16 février 2024
BRUIN-MCL-321: A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Essai Clinique (Loxo Oncology, Inc.)   24 janvier 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse.
American journal of hematology   30 novembre 2023
Highly Sensitive Interleukin Score for Intra-Ocular Lymphoma Diagnosis: Evidence from Analysis of 5-Year Real-Life of Use
65th ASH Annual Meeting Abstracts   02 novembre 2023
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Blood advances   24 octobre 2023
P14.08.A PROGNOSTIC VALUE OF CSF IL-10 AT THE 2-MONTH ASSESSMENT AFTER THE START OF INDUCTION CHEMOTHERAPY IN PRIMARY CNS LYMPHOMAS. A LOC NETWORK STUDY
Abstracts from the 18th Meeting of the European Association of Neuro-Oncology   08 septembre 2023
JS03.6.A NEUROTOXICITY IN PATIENTS WITH CNS LYMPHOMAS TREATED WITH CAR T CELL THERAPY. A LOC NETWORK STUDY
Abstracts from the 18th Meeting of the European Association of Neuro-Oncology   08 septembre 2023